Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 9, 2026

Augmentation de capital de 8 M€ réalisée avec succès

View original at globenewswire.com
Augmentation de capital de 8 M€ réalisée avec succès Paris, le 9 février 2026, 19h00 CET, Audacia (FR00140059B5 – ALAUD), entreprise de private equity spécialisée dans le Capital Développement, le Capital Immobilier et le Capital Innovation, reconnue pour ses thèses d’investissement pionnières, notamment dans les techn…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Since its creation, Audacia has invested more than one billion euros in more than 400 companies

    80% confidence

  • This fundraising allows us to accelerate the development of our thematic funds, continue our specialization policy by launching new vehicles and selectively study external growth opportunities

    80% confidence

  • The capital increase received total demand of 1,975,308 new shares at €4.05 per share, representing 100% of the capital increase amount

    80% confidence

  • We will continue to deploy the Audacia model as an agile and unique investment platform in future-oriented themes, serving performance and value creation for all stakeholders

    80% confidence

  • Manitoba Capital and Audacia share the same conviction: to strengthen the strategic independence of Europe and France and work towards sustainable prosperity

    80% confidence

  • The success of this capital increase validates the direction we have set and underscores the confidence of our shareholders in our model of supporting audacious entrepreneurs responding to the major challenges of our time

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com